奥曲肽联合乌司他丁治疗急性重症胰腺炎临床疗效及安全性评估

Clinical Efficacy and Safety of Statins Octreotide Combined With Ulinastatin in Treatment of Severe Acute Pancreatitis

目的分析奥曲肽联合乌司他丁治疗急性重症胰腺炎（SAP）临床疗效及安全性。方法选取2014年2月~2015年3月收治的40例急性重症胰腺炎患者,随机分成对照组和观察组各20例,对照组实施奥曲肽治疗,观察组实施（奥曲肽＋乌司他丁）治疗,对比两组患者治疗效果。结果观察组尿淀粉酶恢复时间、血清淀粉酶恢复时间、住院时间低于对照组（P〈0.05）;观察组治疗总有效率（98%）优于对照组（86%）,结论奥曲肽联合乌司他丁治疗急性重症胰腺炎临床疗效显著,安全性高。

Objective To analyze the efficacy and safety of octreotide combined with ulinastatin in the treatment of severe acute pancreatitis（SAP）. Methods From February 2014 to March 2015, 40 cases of severe acute pancreatitis patients were randomly divided into control group and observation group,each group had 20 cases, control group received octreotide treatment, observation group received octreotide ＋ Ulinastatin, compared the effect in two groups. Results In the observation group, serum amylase, urine amylase recovery time, recovery time of hospitalization was significantly lower than that of the control group（P〈0. 05）, the total efficiency of the observation group（98%） was significantly better than the control group（86%）. Conclusion Clinical curative effect of octreotide combined with ulinastatin in the treatment of severe acute pancreatitis is good, and it has high safety.